CRP tracked with early stroke severity in small-vessel occlusion
In minor acute ischaemic stroke, systemic inflammation is often assumed to carry prognostic weight, yet this study showed a narrower and more selective pattern than many clinicians might expect. Among 64 patients with predominantly mild presentations, admission C-reactive protein CRP aligned with neurological severity only in the small-vessel occlusion subgroup, where higher CRP correlated with admission NIHSS, 1-month NIHSS, and admission mRS. The signal was not broad-based across all stroke mechanisms. It emerged in one aetiological subgroup and faded outside it.
The cohort was small but clinically relevant: 36 patients had small-vessel occlusion and 28 fell into non-SVO categories, while the median admission NIHSS was 2. In that setting, CRP behaved less like a universal prognostic biomarker and more like a marker that may mirror the burden of vascular injury in lacunar-type stroke. Small-vessel disease is tightly linked to endothelial dysfunction, blood-brain barrier disturbance, and microvascular inflammation, so a relationship between CRP and neurological deficit is biologically plausible. The association suggests that even modest systemic inflammatory activation may reflect the intensity of the acute event when the culprit lesion lies in the penetrating arteries.
One result stood out with particular clarity. Admission NIHSS predicted both 1-month neurologic status and functional outcome across the full cohort.
Baseline neurological deficit dominated 1-month outcome prediction
The statistical models were disciplined rather than expansive. Correlations were adjusted using Benjamini–Hochberg correction, and separate Poisson and Firth models tested 1-month NIHSS and functional independence, defined as mRS 0–1 versus 2–6, with and without admission NIHSS. Once baseline severity entered the models, none of the inflammatory biomarkers retained an independent association with either 1-month outcome. In other words, the early clinical examination carried more predictive weight than the biomarker panel.
Admission NIHSS was associated with 1-month NIHSS in both models, with mean ratios of 1.30 to 1.32, and with mRS 2–6 at 1 month, with odds ratios of 2.25 to 2.32; all p values were below 0.001. Those estimates are clinically intuitive. A patient who arrives with a more severe focal deficit is less likely to normalize quickly, even when the presenting stroke is classified as minor. The biology is straightforward: initial neurologic impairment captures infarct location, lesion load, and the immediate physiological consequences of ischemia more directly than any circulating acute-phase marker can.
Among the 64 patients, 11 had a 1-month mRS score of 2–6, a reminder that “minor” stroke does not always translate into a benign short-term course. Functional decline after a mild ischemic event may be modest in absolute terms, but it is still meaningful at the bedside, particularly when gait, hand function, or speech remain impaired enough to disrupt independence.
A selective inflammatory signal, not a universal one
The biomarker pattern differed by stroke subtype. In the non-SVO group, CRP correlated with ferritin, but no biomarker-clinical score association survived multiple-testing adjustment. Ferritin and CRP both reflect inflammatory activity, yet their linkage does not automatically translate into outcome prediction. In larger-vessel or embolic mechanisms, stroke severity may depend more on clot burden, recanalization dynamics, collateral flow, or the timing of reperfusion than on systemic inflammation at admission.
This is where the study becomes especially useful. It does not argue that inflammation is irrelevant. It argues that a circulating inflammatory marker may not add much once clinicians already know the patient’s initial NIHSS, at least in a small cohort with mostly minor stroke. The data fit a familiar problem in stroke medicine: biologic plausibility does not guarantee incremental prognostic value. A marker can correlate with disease activity and still fail to improve bedside prediction beyond a strong clinical exam.
The systemic immune-inflammation index did not emerge as an independent predictor either. In a cohort this compact, a null finding cannot exclude a real effect, but it does limit any claim that routine inflammatory panels should guide 1-month prognostication after minor ischemic stroke.
What the findings mean for acute stroke assessment
For clinicians, the practical message is restrained. Admission NIHSS remains the anchor for short-term outcome assessment in minor acute ischemic stroke, and inflammatory biomarkers should not replace it. CRP may still deserve attention in small-vessel occlusion, where it tracked both acute neurological burden and 1-month NIHSS, but the study could not establish that this relationship is strong enough to stand independently of established clinical measures. The subgroup signal is intriguing because it points toward a vascular inflammation phenotype in lacunar stroke, yet it stops short of changing routine practice.
The design also sets natural boundaries on interpretation. This was a prospective single-centre study with 64 patients, a size that limits power, especially after stratification by stroke subtype. Only 17.2% of the cohort had a 1-month mRS score of 2–6, so outcome events were few. With a small sample and several correlated biomarkers, the chance of missing a modest independent effect remains real. A larger cohort would be needed to test whether CRP adds value in a way that meaningfully improves risk stratification beyond NIHSS and standard clinical variables.
Even with those limits, the study answers an important question in a practical way: when a patient presents with a minor ischemic stroke, the neurologic exam still carries more prognostic information than the inflammatory panel. CRP may echo the severity of small-vessel disease, but it did not displace the bedside assessment that neurologists already rely on.